Bulletin of Semashko National Research Institute of Public HealthBulletin of Semashko National Research Institute of Public Health2415-84102415-8429FSSBI «N.A. Semashko National Research Institute of Public Health»2511Материалы конференцииStudying disproportions in the development of pharmaceutical science: a global aspectSokolovaE. V.anfalova739@mail.ruGuryanovP. S.laboratory.iot@gmail.comPerm State Pharmaceutical Academy (PSFA)15122022415716025112022Copyright © 2022,2022The paper considers the dynamics of the development of the global pharmaceutical industry in the «Center-Periphery» model. A number of main trends and disproportions accompanying this development have been identified.Big Pharmapharmaceutical industry«Center-Periphery» modelworld-systemBig Pharmadisproportionsфармацевтическая индустриямодель «Центр-Периферия»мир-системадиспропорции1.Хайрутдинов, А. Р. Мир-системный анализ в географии международной торговли / А. Р. Хайрутдинов // Географический вестник. - 2011. - № 2(17). - С. 21-25.2.Ornaghi A. Mergers and innovation in big pharma.International Journal of Industrial Organization. 2009;27(1):70-79. doi: https://doi.org/10.1016/j.ijindorg.2008.04.0033.Gautam A. The changing model of big pharma: impact of key trends. Drug Discovery Today. 2015; 21(3):379-384, doi: https://doi.org/10.1016/j.drudis.2015.10.002.4.Rottingen J. Mapping of available health research and development data: what`s there, what`s missing, and what role is there for a global observatory? The Lancet. 2013; 382: 1286-1307. doi: http://dx.doi.org/10.1016/S0140-6736(13)61046-65.Rafols I. Big Pharma, little science? A bibliometric perspective on Big Pharma's R&D decline. Technological Forecasting & Social Change.2012; doi:10.1016/j.techfore.2012.06.007